Littelfuse shares rallied sharply following the closure of its Basler Electric acquisition, alongside stronger-than-expected Q1 2026 sales guidance and a new dividend declaration, despite posting a significant net loss for Q4 2025.
Viasat shares have rocketed 31% in a month, reigniting investor debate over whether the satellite communications firm is a hidden gem or a momentum-driven play facing stiff competition from SpaceX's Starlink and Amazon's Project Kuiper.
A wave of protests and student walkouts swept across the United States on Friday, demanding the withdrawal of federal immigration agents from Minnesota following fatal shootings, as political tensions threaten a government shutdown.
As the Super Bowl kicks off in California—a state without legal sports betting—federally regulated prediction markets are positioned to siphon off a significant portion of wagering activity, potentially reaching record trading volumes this year.
A dramatic sell-off in precious metals, led by a record-breaking drop in silver, rattled financial markets on January 30, 2026, as a surging U.S. dollar and shifting expectations for Federal Reserve policy triggered a broad retreat from risk assets.
Deutsche Bank reported meeting its key 2025 financial objectives, including a 10.3% return on tangible equity, and outlined a path to boost profitability above 13% by 2028. The update, delivered during a fixed income call, highlighted revenue growth, cost discipline, and a strengthened balance sheet, even as management signaled caution on parts of the commercial real estate market.
Buoyed by strategic brand exits and tariff mitigation, Church & Dwight enters 2026 with robust cash flow and a sharpened focus on its 'power brands' like Arm & Hammer and TheraBreath, despite a challenging consumer landscape.
Gatsby Chocolate, the 'healthy' indulgence that captivated Sharks and shoppers alike, has vanished from shelves. We trace its journey from a multi-million dollar deal that never closed to its quiet demise, exploring what went wrong for a once-promising brand.
Private equity giant Thoma Bravo is exploring a sale of Imprivata, a key player in healthcare digital identity software, in a deal that could value the company at up to $7 billion, sources tell Reuters.
Cocoa futures have plunged to multi-year lows, pressured by a global surplus and weakening demand as high chocolate prices curb consumption. Analysts point to favorable harvests in West Africa and falling processing volumes as key factors extending the market's month-long decline.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
Realtor.com ranks the Florida Keys among the nation's top luxury markets, where strict development limits and finite land create a high-stakes arena for elite buyers seeking a unique legacy, not just a second home.
In a landmark disclosure during its Q4 earnings call, Tesla has revealed it now has 1.1 million active Full Self-Driving (FSD) subscribers worldwide. The announcement comes as the company prepares to shift exclusively to a monthly subscription model, a strategic move tied to Elon Musk's ambitious goal of reaching 10 million active users.
The Louisville-based regional bank's significant purchase of its own stock highlights internal optimism amid a shifting interest rate landscape, even as it trimmed holdings in tech giants.
Barrick Gold's stock has soared over 220% in the past year, leaving investors to question if the rally has peaked. A deep dive into valuation metrics suggests the mining giant may still be trading at a significant discount to its intrinsic value.
The new year kicked off with significant personnel changes in the human resources executive suite, highlighting strategic expansions of roles and notable returns to former companies.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
The $10 to $50 per share range is a hunting ground for investors seeking established, mid-sized companies with growth potential. While often less volatile than penny stocks, they are not without risk. We analyze one stock with promising upside and two facing significant headwinds.
High valuations demand exceptional growth. We examine two companies whose business models justify the premium and one where the price may be running ahead of reality.
